M0064 – Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

Long description

Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

Short description

Visit for drug monitoring

Pricing indicator

11 Priced using national RVUs (Physician Fee Schedule)

Medicare coverage

D Special coverage instructions apply

BETOS category

M5B Specialist - psychiatry

Added

January 1, 1992

Last change

January 1, 2015 – No change

Termination date

December 31, 2014

Nearby M codes

• M0001 – Advancing cancer care mips value pathways
• M0002 – Optimal care for kidney health mips value pathways
• M0003 – Optimal care for patients with episodic neurological conditions mips value pathways
• M0004 – Quality care for patients with neurological conditions mips value pathway
• M0005 – Value in primary care mips value pathway
• M0010 – Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
• M0075 – Cellular therapy
• M0076 – Prolotherapy
• M0100 – Intragastric hypothermia using gastric freezing
• M0201 – Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home
• M0220 – Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring
• M0221 – Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
• M0222 – Intravenous injection, bebtelovimab, includes injection and post administration monitoring
• M0223 – Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency